Comment
Author: Admin | 2025-04-28
For more than 145 years, we have been working tirelessly to develop and deliver medicines that meet real needs. UK laws and regulations limit the amount of product information that we can provide to the public on our website. The product information on this website is intended for UK residents over the age of eighteen years only. Medicines Abasaglar ® (insulin glargine) Adcirca ® (tadalafil)**Alimta ® (pemetrexed)Baricitinib LillyCialis ® (tadalafil)Cymbalta ® (duloxetine)Cyramza ® (ramucirumab)Emgality ® (galcanezumab)**Forsteo ® (teriparatide)Humalog ® (human insulin analogue)Humulin ® (human insulin)Jardiance ® (empagliflozin)*Kisunla ® ▼ (donanemab) Lyumjev ® (insulin lispro)Mounjaro ® ▼ (tirzepatide)Omvoh ® ▼ (mirikizumab)Retsevmo ® ▼ (selpercatinib)Strattera ® (atomoxetine) Taltz ® (ixekizumab)Trulicity ® (dulaglutide)Verzenios ® (abemaciclib)Yentreve ® (duloxetine) To view Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit:For England, Scotland, Wales: https://www.medicines.org.uk/emc/For Northern Ireland and Ireland: https://www.medicines.ie/* Lilly is not the marketing authorisation holder (MAH) but either promotes, markets or distributes this product.**Lilly is the marketing authorisation holder (MAH) but does not promote this product.Report an Adverse Event or Product ComplaintIf you experience side effects taking a Lilly medicine, talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide information on the safety of medicines.Please do not use this website to report side effects or complaints about a Lilly product. To report a side effect or product complaint with a Lilly product please call Lilly UK. Call 01256 315000 Or email
Add Comment